Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF 100 Equity-to-Asset is 0.82 as of Jun. 2026, which is 1% below its 10-year median of 0.83. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.79 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, BioGaia AB ranks better than 82.7% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioGaia AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $115.7 Mil. BioGaia AB's Total Assets for the quarter that ended in Jun. 2026 was $140.4 Mil.
Therefore, BioGaia AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.82.
The historical rank and industry rank for BioGaia AB's Equity-to-Asset or its related term are showing as below:
BGLAF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7 Med: 0.83 Max: 0.94
Current: 0.82
During the past 13 years, the highest Equity to Asset Ratio of BioGaia AB was 0.94. The lowest was 0.70. And the median was 0.83.
BGLAF's Equity-to-Asset is ranked better than 82.7% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs BGLAF: 0.82
BioGaia AB (OTCPK:BGLAF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioGaia AB Equity-to-Asset Related Terms
BioGaia AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioGaia AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioGaia AB and its competitors. This is near median its historical median of 0.83. Over the past decade, BioGaia AB's Equity-to-Asset has ranged from 0.70 to 0.94. According to the industry distribution chart, BioGaia AB ranks #174 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 17.3%.
Is BioGaia AB's Equity-to-Asset too high?
BioGaia AB's current Equity-to-Asset of 0.82 is near median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 0.94. The Drug Manufacturers industry median Equity-to-Asset is 0.61. BioGaia AB's value of 0.82 is 34.4% above this industry median. Based on the distribution chart, BioGaia AB ranks #174 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #174 out of 1006 companies for Equity-to-Asset. This places BioGaia AB in the top 17% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. BioGaia AB's value of 0.82 is 34.4% above this benchmark. Historically, BioGaia AB's own Equity-to-Asset has ranged from 0.70 to 0.94 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 0.61, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Equity-to-Asset of 0.82 is 34.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.79, compared to a current price of $12.20 — trading 4.6% below its estimated fair value. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.83 and 34.4% above the Drug Manufacturers industry median of 0.61. BioGaia AB's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 4.6% below its estimated GF Value™ of $12.79.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Equity-to-Asset: 0.82 (near median its 10-year median of 0.83)
GF Value™: $12.79 vs. price of $12.20 (4.6% below fair value)
Industry Position: 34.4% above the Drug Manufacturers median (#174 of 1006)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
